Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Accumulated Expenses (2016 - 2020)

Myriad Genetics has reported Other Accumulated Expenses over the past 7 years, most recently at $22.4 million for Q2 2020.

  • Quarterly Other Accumulated Expenses rose 146.15% to $22.4 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Jun 2020, up 146.15% year-over-year, with the annual reading at $22.4 million for FY2020, 146.15% up from the prior year.
  • Other Accumulated Expenses was $22.4 million for Q2 2020 at Myriad Genetics, up from $4.3 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $22.4 million in Q2 2020 and troughed at $4.3 million in Q1 2020.
  • The 5-year median for Other Accumulated Expenses is $13.8 million (2016), against an average of $13.5 million.
  • The largest YoY upside for Other Accumulated Expenses was 146.15% in 2020 against a maximum downside of 80.09% in 2020.
  • A 5-year view of Other Accumulated Expenses shows it stood at $13.7 million in 2016, then rose by 13.87% to $15.6 million in 2017, then grew by 13.46% to $17.7 million in 2018, then tumbled by 53.67% to $8.2 million in 2019, then soared by 173.17% to $22.4 million in 2020.
  • Per Business Quant, the three most recent readings for MYGN's Other Accumulated Expenses are $22.4 million (Q2 2020), $4.3 million (Q1 2020), and $8.2 million (Q4 2019).